Sin-Ho Jung

List of Publications by Year
in descending order

135 papers	5,200 citations	147801 31 h-index	95266 68 g-index
136 all docs	136 docs citations	136 times ranked	8835 citing authors

#	Article	IF	Citations
1	Survival and tumor characteristics of patients presenting with single primary versus second primary melanoma lesions. Journal of the American Academy of Dermatology, 2023, 88, 1033-1039.	1.2	2
2	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. Journal of Clinical Oncology, 2023, 41, 336-342.	1.6	9
3	Diagnostic Performance of an Artificial Intelligence System in Breast Ultrasound. Journal of Ultrasound in Medicine, 2022, 41, 97-105.	1.7	23
4	Group sequential testing for cluster randomized trials with time–to–event endpoint. Biometrics, 2022, 78, 1353-1364.	1.4	0
5	Home-Based Hematopoietic Cell Transplantation in the United States. Transplantation and Cellular Therapy, 2022, 28, 207.e1-207.e8.	1.2	3
6	Initial Clinical Outcome With Bilateral, Dual-Target Deep Brain Stimulation Trial in Parkinson Disease Using Summit RC + S. Neurosurgery, 2022, 91, 132-138.	1.1	8
7	Investigating readmission rates for patients undergoing oncologic resection and endoprosthetic reconstruction for primary sarcomas and tumors involving bone. Journal of Surgical Oncology, 2022, , .	1.7	1
8	Financial incentives to increase stool collection rates for microbiome studies in adult bone marrow transplant patients. PLoS ONE, 2022, 17, e0267974.	2.5	0
9	The Contribution of Material, Behavioral, Psychological, and Social-Relational Factors to Income-Related Disparities in Cardiovascular Risk Among Older Adults. Journal of Cardiovascular Nursing, 2021, Publish Ahead of Print, .	1.1	0
10	Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 262.e1-262.e11.	1.2	7
11	Randomised, double-blind, placebo-controlled trial of Probiotics To Eliminate COVID-19 Transmission in Exposed Household Contacts (PROTECT-EHC): a clinical trial protocol. BMJ Open, 2021, 11, e047069.	1.9	26
12	Design and Analysis of Cancer Clinical Trials for Personalized Medicine. Journal of Personalized Medicine, 2021, 11, 376.	2.5	2
13	Outcomes of adjunctive therapies post hedgehog inhibitors in the management of locally advanced basal cell carcinoma: A systematic review and pooled analysis. Dermatologic Therapy, 2021, 34, e15172.	1.7	3
14	Sample size calculation for clustered survival data under subunit randomization. Lifetime Data Analysis, 2021, , 1.	0.9	0
15	Sample size calculation for cluster randomization trials with a time–to–event endpoint. Statistics in Medicine, 2020, 39, 3608-3623.	1.6	5
16	Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma. Anticancer Research, 2020, 40, 5245-5254.	1.1	14
17	Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. PLoS ONE, 2020, 15, e0238824.	2.5	4
18	A 10-year trend in income disparity of cardiovascular health among older adults in South Korea. SSM - Population Health, 2020, 12, 100682.	2.7	2

#	ARTICLE	IF	CITATIONS
19	Nomogram to predict lymph node metastasis in patients with early gastric cancer: a useful clinical tool to reduce gastrectomy after endoscopic resection. Endoscopy, 2020, 52, 435-443.	1.8	41
20	Sinonasal Squamous Cell Carcinoma Outcomes: Does Treatment at a High-Volume Center Confer Survival Benefit?. , 2020, 81, .		0
21	Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance).. Journal of Clinical Oncology, 2020, 38, e13535-e13535.	1.6	0
22	Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.. Journal of Clinical Oncology, 2020, 38, 8038-8038.	1.6	1
23	Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with highâ€risk follicular lymphoma: CALGB 50904 (Alliance). Cancer, 2019, 125, 3378-3389.	4.1	10
24	156. Clinical Characteristics and Acute-phase Cytokine Response of Solid-Organ Transplant Recipients with Bloodstream Infections Differs According to Bacterial Type and Transplant Status. Open Forum Infectious Diseases, 2019, 6, S104-S104.	0.9	0
25	<i>K</i>â€Sample comparisons using propensity analysis. Biometrical Journal, 2019, 61, 698-713.	1.0	1
26	Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelated Donors. Blood, 2019, 134, 4613-4613.	1.4	2
27	Daily Chlorhexidine Gluconate Bathing Reduces the Rate of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 2210-2210.	1.4	0
28	Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality. Blood, 2019, 134, 5731-5731.	1.4	0
29	Imaging genotyping of functional signaling pathways in lung squamous cell carcinoma using a radiomics approach. Scientific Reports, 2018, 8, 3284.	3.3	20
30	Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). Journal of Geriatric Oncology, 2018, 9, 321-328.	1.0	5
31	Iodized Oil Transarterial Chemoembolization and Radiofrequency Ablation for Small Periportal Hepatocellular Carcinoma: Comparison with Nonperiportal Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2018, 41, 120-129.	2.0	3
32	The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing. Sarcoma, 2018, 2018, 1-7.	1.3	14
33	Influence of vitamin D (Vit D) on mammographic density (MD) and insulin like growth factor 1 (IGF1): Results of CALGB (Alliance) 70806.. Journal of Clinical Oncology, 2018, 36, 1549-1549.	1.6	2
34	Optimal two-stage log-rank test for randomized phase II clinical trials. Journal of Biopharmaceutical Statistics, 2017, 27, 639-658.	0.8	0
35	Obesity-related parameters and colorectal adenoma development. Journal of Gastroenterology, 2017, 52, 1221-1229.	5.1	16
36	Preservation of the endometrial enhancement after magnetic resonance imaging-guided high-intensity focused ultrasound ablation of submucosal uterine fibroids. European Radiology, 2017, 27, 3956-3965.	4.5	16

#	Article	IF	Citations
37	Gadoxetic acid-enhanced magnetic resonance imaging characteristics of hepatocellular carcinoma occurring in liver transplants. European Radiology, 2017, 27, 3117-3127.	4.5	4
38	Uterine fibroids: Influence of â€œT2-Rim signâ€•on immediate therapeutic responses to magnetic resonance imaging-guided high-intensity focused ultrasound ablation. European Journal of Radiology, 2017, 97, 21-30.	2.6	6
39	Design of phase II non-inferiority trials. Contemporary Clinical Trials Communications, 2017, 7, 23-27.	1.1	5
40	Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis. Journal of Gastroenterology, 2017, 52, 594-601.	5.1	47
41	A prediction model for advanced colorectal neoplasia in an asymptomatic screening population. PLoS ONE, 2017, 12, e0181040.	2.5	29
42	CALGB/ECOG 100104 (Alliance) study: Lenalidomide (LEN) vs placebo (PBO) maintenance (maint) after stem cell transplant (SCT) for patients (pts) with multiple myelomaâ€"Overall survival (OS) and progression-free survival (PFS) adjusted for treatment (tx) crossover (XO).. Journal of Clinical Oncology, 2017, 35, 8037-8037.	1.6	1
43	Dynamic prognostication using conditional survival analysis for patients with operable lung adenocarcinoma. Oncotarget, 2017, 8, 32201-32211.	1.8	16
44	Risk score model for the development of hepatocellular carcinoma in treatment-naÃ¯ve patients receiving oral antiviral treatment for chronic hepatitis B. Clinical and Molecular Hepatology, 2017, 23, 170-178.	8.9	49
45	Phase II Trials for Heterogeneous Patient Populations with a Time-to-Event Endpoint. Medical Research Archives, 2017, 5, .	0.2	1
46	Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2017, 35, TPS7566-TPS7566.	1.6	1
47	Nomogram for lymph node metastasis prediction with early gastric cancer patients: To decide additional gastrectomy after endoscopic dissection.. Journal of Clinical Oncology, 2017, 35, 4045-4045.	1.6	0
48	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget, 2016, 7, 6984-6993.	1.8	134
49	Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget, 2016, 7, 47794-47807.	1.8	24
50	A Risk Prediction Model Based on Lymph-Node Metastasis in Poorly Differentiatedâ€"Type Intramucosal Gastric Cancer. PLoS ONE, 2016, 11, e0156207.	2.5	10
51	Diabetic biomarkers and the risk of proximal or distal gastric cancer. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1705-1710.	2.8	15
52	FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Modern Pathology, 2016, 29, 1095-1103.	5.5	70
53	A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. Molecular Diagnosis and Therapy, 2016, 20, 375-383.	3.8	13
54	Evaluation of the risk factors associated with rectal neuroendocrine tumors: a big data analytic study from a health screening center. Journal of Gastroenterology, 2016, 51, 1112-1121.	5.1	19

#	ARTICLE	IF	CITATIONS
55	Clinicopathological Features and Prognosis of Mixed-Type T1a Gastric Cancer Based on Lauren's Classification. Annals of Surgical Oncology, 2016, 23, 784-791.	1.5	20
56	The recommended treatment algorithms of the <scp>BCLC</scp> and <scp>HKLC</scp> staging systems: does following these always improve survival rates for <scp>HCC</scp> patients?. Liver International, 2016, 36, 1490-1497.	3.9	51
57	Safety of Percutaneous Biopsy for Hepatic Angiosarcoma: Results of a Multicenter Korean Survey. Journal of Vascular and Interventional Radiology, 2016, 27, 846-851.	0.5	13
58	Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma. European Radiology, 2016, 26, 3437-3446.	4.5	24
59	Coronary Microvascular Dysfunction as a Mechanism of Angina in Severe AS. Journal of the American College of Cardiology, 2016, 67, 1412-1422.	2.8	52
60	The effects of cytotoxic therapy in progressive IgA nephropathy. Annals of Medicine, 2016, 48, 171-181.	3.8	7
61	The impact of slow graft function on graft outcome is comparable to delayed graft function in deceased donor kidney transplantation. International Urology and Nephrology, 2016, 48, 431-439.	1.4	12
62	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncology, The, 2016, 17, 389-400.	10.7	285
63	Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). Radiotherapy and Oncology, 2016, 118, 244-250.	0.6	43
64	Clinical outcome and predictors of treatment response in foam sodium tetradecyl sulfate sclerotherapy of venous malformations. European Radiology, 2016, 26, 1301-1310.	4.5	35
65	A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13.. Journal of Clinical Oncology, 2016, 34, 9043-9043.	1.6	1
66	Serum protein profiling using an aptamer array predicts clinical outcomes of stage IIA colon cancer: A leave-one-out crossvalidation. Oncotarget, 2016, 7, 16338-16348.	1.8	7
67	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. Oncotarget, 2016, 7, 24088-24096.	1.8	15
68	Randomized trial of subfascial infusion of ropivacaine for early recovery in laparoscopic colorectal cancer surgery. Korean Journal of Anesthesiology, 2016, 69, 604.	2.5	12
69	Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. Gut and Liver, 2016, 10, 796-802.	2.9	14
70	Comparison of operational characteristics for binary tests with clustered data. Statistics in Medicine, 2015, 34, 2325-2333.	1.6	9
71	T2-Weighted Liver MRI Using the MultiVane Technique at 3T: Comparison with Conventional T2-Weighted MRI. Korean Journal of Radiology, 2015, 16, 1038.	3.4	21
72	Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. Journal of Korean Medical Science, 2015, 30, 1618.	2.5	12

#	Article	IF	Citations
73	A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. International Journal of Cancer, 2015, 136, 1976-1984.	5.1	17
74	Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematology,the, 2015, 2, e66-e74.	4.6	85
75	Lymphoepithelioma-like carcinoma: A distinct type of gastric cancer. Journal of Surgical Research, 2015, 194, 458-463.	1.6	27
76	Optimal Estimation for Regression Models on $\ddot{I}_{,,}$-Year Survival Probability. Journal of Biopharmaceutical Statistics, 2015, 25, 539-547.	0.8	0
77	Development and external validation of nomograms predictive of response to radiation therapy and overall survival in nasopharyngeal cancer patients. European Journal of Cancer, 2015, 51, 1303-1311.	2.8	40
78	Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non–Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. Journal of Clinical Oncology, 2015, 33, 2450-2456.	1.6	61
79	Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials. Contemporary Clinical Trials, 2015, 42, 9-17.	1.8	10
80	Practical approach to determine sample size for building logistic prediction models using high-throughput data. Journal of Biomedical Informatics, 2015, 53, 355-362.	4.3	5
81	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Medicine, 2015, 21, 449-456.	30.7	1,592
82	Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 331-337.	1.1	163
83	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). Breast Cancer Research and Treatment, 2015, 152, 77-85.	2.5	17
84	Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of Clinical Oncology, 2015, 33, 3635-3640.	1.6	163
85	Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04. Journal of Clinical Oncology, 2015, 33, 2660-2666.	1.6	215
86	Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leukemia and Lymphoma, 2015, 56, 958-964.	1.3	36
87	Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. Oncotarget, 2015, 6, 38372-38380.	1.8	47
88	Type I Error Control for Tree Classification. Cancer Informatics, 2014, 13s7, CIN.S16342.	1.9	4
89	Statistical Issues in the Design and Analysis of nCounter Projects. Cancer Informatics, 2014, 13s7, CIN.S16343.	1.9	6
90	Randomized Phase II Clinical Trials. Journal of Biopharmaceutical Statistics, 2014, 24, 802-816.	0.8	11

#	Article	IF	Citations
91	Clinical relevance of procalcitonin and C-reactive protein as infection markers in renal impairment: a cross-sectional study. Critical Care, 2014, 18, 640.	5.8	35
92	Stratified Fisher's exact test and its sample size calculation. Biometrical Journal, 2014, 56, 129-140.	1.0	75
93	Phase II clinical trials with time‐to‐event endpoints: optimal two‐stage designs with one‐sample log‐rank test. Statistics in Medicine, 2014, 33, 2004-2016.	1.6	33
94	CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells. Cancer Immunology Research, 2014, 2, 878-889.	3.4	48
95	A randomized trial of diet in men with early stage prostate cancer on active surveillance: Rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). Contemporary Clinical Trials, 2014, 38, 198-203.	1.8	27
96	Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202. Blood, 2014, 124, 3091-3091.	1.4	28
97	CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.. Journal of Clinical Oncology, 2014, 32, 8521-8521.	1.6	12
98	Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Investigational New Drugs, 2013, 31, 1580-1586.	2.6	33
99	Appropriate Design of Prospective Studies. Journal of Clinical Oncology, 2013, 31, 510-511.	1.6	7
100	Sample Size Considerations of Prediction‐Validation Methods in High‐Dimensional Data for Survival Outcomes. Genetic Epidemiology, 2013, 37, 276-282.	1.3	29
101	A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer, 2013, 119, 3797-3804.	4.1	47
102	Designs for randomized phase II clinical trials with two treatment arms. Statistics in Medicine, 2013, 32, 4367-4379.	1.6	4
103	Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance). Blood, 2013, 122, 3002-3002.	1.4	2
104	Power and Sample Size Calculation for Microarray Studies. Journal of Biopharmaceutical Statistics, 2012, 22, 30-42.	0.8	26
105	On Sample Size Calculation for Comparing Survival Curves Under General Hypothesis Testing. Journal of Biopharmaceutical Statistics, 2012, 22, 485-495.	0.8	15
106	Phase II Cancer Clinical Trials with Heterogeneous Patient Populations. Journal of Biopharmaceutical Statistics, 2012, 22, 312-328.	0.8	13
107	CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma.. Journal of Clinical Oncology, 2012, 30, 8000-8000.	1.6	16
108	Statistical Considerations for Analysis of Microarray Experiments. Clinical and Translational Science, 2011, 4, 466-477.	3.1	28

#	Article	IF	Citations
109	Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,. Blood, 2011, 118, 3644-3644.	1.4	3
110	Reply to K. Shimada et al. Journal of Clinical Oncology, 2010, 28, e230-e230.	1.6	1
111	Between-Arm Comparisons in Randomized Phase II Trials. Journal of Biopharmaceutical Statistics, 2009, 19, 456-468.	0.8	11
112	Sample size calculation for microarray experiments with blocked one-way design. BMC Bioinformatics, 2009, 10, 164.	2.6	1
113	Randomized phase II trials with a prospective control. Statistics in Medicine, 2008, 27, 568-583.	1.6	53
114	Sample size calculation for the weighted rank statistics with paired survival data. Statistics in Medicine, 2008, 27, 3350-3365.	1.6	12
115	Sample size calculation for the log-rank tests for multi-arm trials with a control. Journal of the Korean Statistical Society, 2008, 37, 11-22.	0.4	5
116	Designing phase II studies in cancer with time-to-event endpoints. Clinical Trials, 2008, 5, 209-221.	1.6	14
117	Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502. Blood, 2008, 112, 232-232.	1.4	7
118	Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.. Blood, 2008, 112, 1460-1460.	1.4	0
119	Sample Size Calculation for Weighted Rank Tests Comparing Survival Distributions Under Cluster Randomization: A Simulation Method. Journal of Biopharmaceutical Statistics, 2007, 17, 839-849.	0.8	8
120	A Note on Sample Size Calculation Based on Propensity Analysis in Nonrandomized Trials. Journal of Biopharmaceutical Statistics, 2007, 17, 35-41.	0.8	17
121	Rank tests for clustered survival data when dependent subunits are randomized. Statistics in Medicine, 2006, 25, 361-373.	1.6	13
122	How accurately can we control the FDR in analyzing microarray data?. Bioinformatics, 2006, 22, 1730-1736.	4.1	25
123	p-Value Calculation for Multistage Phase II Cancer Clinical Trials. Journal of Biopharmaceutical Statistics, 2006, 16, 765-775.	0.8	18
124	A multiple testing procedure to associate gene expression levels with survival. Statistics in Medicine, 2005, 24, 3077-3088.	1.6	24
125	Sample size calculation for multiple testing in microarray data analysis. Biostatistics, 2005, 6, 157-169.	1.5	90
126	Sample Size Computation for Two-Sample Noninferiority Log-Rank Test. Journal of Biopharmaceutical Statistics, 2005, 15, 969-979.	0.8	35

#	Article	IF	Citations
127	Sample size for FDR-control in microarray data analysis. Bioinformatics, 2005, 21, 3097-3104.	4.1	111
128	Sample Size Calculation for Simulation-Based Multiple-Testing Procedures. Journal of Biopharmaceutical Statistics, 2005, 15, 957-967.	0.8	17
129	Admissible two-stage designs for phase II cancer clinical trials. Statistics in Medicine, 2004, 23, 561-569.	1.6	134
130	On the estimation of the binomial probability in multistage clinical trials. Statistics in Medicine, 2004, 23, 881-896.	1.6	84
131	Rank tests for clustered survival data. Lifetime Data Analysis, 2003, 9, 21-33.	0.9	28
132	Sample size estimation for GEE method for comparing slopes in repeated measurements data. Statistics in Medicine, 2003, 22, 1305-1315.	1.6	78
133	Sample size calculation for rank tests comparing K survival distributions. Lifetime Data Analysis, 2002, 8, 361-373.	0.9	13
134	Sample size calculations for clustered binary data. Statistics in Medicine, 2001, 20, 1971-1982.	1.6	48
135	Graphical Search for Two-Stage Designs for Phase II Clinical Trials. Contemporary Clinical Trials, 2001, 22, 367-372.	1.9	56